^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EGFRt/19-28z/4-1BBL CAR T cells

i
Other names: EGFRt/19-28z/4-1BBL CAR T cells, CD19-directed 4-1BBL armored CAR, CD19 armored CAR T cell therapy
Associations
Trials
Company:
BMS
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
over1year
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFRt/19-28z/4-1BBL CAR T cells
over2years
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
EGFRt/19-28z/4-1BBL CAR T cells
over3years
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
EGFRt/19-28z/4-1BBL CAR T cells
almost4years
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
EGFRt/19-28z/4-1BBL CAR T cells